Jingyao Biotechnology

Explore the latest insights on Jingyao Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Jingyao Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review
CompanyDeals

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics Inc. (NASDAQ: FHTX) announced that, following a review of clinical data from the Phase 1 dose‑escalation trial of FHD‑909 (LY4050784), both Foghorn and Eli Lilly and Company (NYSE:…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS "Non‑Degradative Molecular Glue" Inhibitor Advances into U.S. Clinical Trials
CompanyDrug

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS “Non‑Degradative Molecular Glue” Inhibitor Advances into U.S. Clinical Trials